Cargando…
Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
Although the molecular landscape of squamous cell carcinoma of the head and neck (SCCHN) has been largely deciphered, only one targeted therapy has been approved to date without any molecular selection, namely cetuximab. Cetuximab is a monoclonal antibody targeting EGFR. It has been shown to improve...
Autores principales: | Saada-Bouzid, Esma, Le Tourneau, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381014/ https://www.ncbi.nlm.nih.gov/pubmed/30815390 http://dx.doi.org/10.3389/fonc.2019.00074 |
Ejemplares similares
-
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008) -
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Agulnik, Mark
Publicado: (2012) -
Targeting PI3K in Cancer: Any Good News?
por: Martini, Miriam, et al.
Publicado: (2013) -
Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014) -
Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer
por: Li, Yingying, et al.
Publicado: (2022)